That entry is looking very very good right now, shucks mine was at .245. Maybe we run to .40 now but need to see the financing done first.
Recent CRDF News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/28/2026 10:13:50 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 04/28/2026 10:11:34 PM
- Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/28/2026 08:01:00 PM
- Cardiff Oncology to Host Key Opinion Leader Discussion on Onvansertib’s Promising Single-Agent Activity • GlobeNewswire Inc. • 04/27/2026 11:00:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/23/2026 08:45:10 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/23/2026 08:44:20 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/23/2026 08:41:21 PM
- Cardiff Oncology to Present Updated Phase 2 Data of Onvansertib in First-Line RAS-Mutated mCRC in a Rapid Oral Session at ASCO 2026 • GlobeNewswire Inc. • 04/21/2026 02:00:00 PM
- Cardiff Oncology Presents Preclinical Data on its PLK1 Inhibitor Onvansertib in Combination with a HER2-Targeted ADC at the 2026 AACR Annual Meeting • GlobeNewswire Inc. • 04/17/2026 08:01:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 04/17/2026 12:08:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/16/2026 08:03:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/16/2026 08:01:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/09/2026 08:10:09 PM
- Cardiff Oncology Announces Key Leadership Appointments to Strengthen Executive Team for Next Phase of Growth • GlobeNewswire Inc. • 04/09/2026 08:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:16:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 08:15:28 PM
- Cardiff Oncology to Host Key Opinion Leader Discussion Focusing on First-Line RAS-mutated Metastatic Colorectal Cancer • GlobeNewswire Inc. • 03/20/2026 11:00:00 AM
- Cardiff Oncology to Present Preclinical Data with Highly Specific PLK1 Inhibitor Onvansertib at the 2026 AACR Annual Meeting • GlobeNewswire Inc. • 03/19/2026 11:00:00 AM
- Cardiff Oncology to Participate in Three Upcoming Investor Conferences • GlobeNewswire Inc. • 02/26/2026 09:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 01:30:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/24/2026 10:09:22 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/24/2026 10:07:45 PM
- Cardiff Oncology Reports Full Year 2025 Results and Provides Business Update • GlobeNewswire Inc. • 02/24/2026 09:30:00 PM
- Cardiff Oncology to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference • GlobeNewswire Inc. • 02/19/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/18/2026 09:02:04 PM
